Parvabumin interneuron-mediated hippocampal network activity disruption in a two-hit model with relevance to postintensive care syndrome: prevention by fluoxetine

**CURRENT STATUS:** POSTED

Mu-huo Ji  
Zhengzhou University

JianHua Tong  
Zhengzhou University

Zhi-qiang Zhou  
Nanjing University

Jian-Jun Yang  
the first hospital of zhengzhou university

✉️ yjyangjj@126.com Corresponding Author

**DOI:**  
10.21203/rs.3.rs-21305/v1

**SUBJECT AREAS**  
Neurobiology of Disease

**KEYWORDS**  
Stress, behavioral outcomes, interneuron, network activity, fluoxetine
Abstract

Background

Postintensive care syndrome (PICS) is defined as a new or worsening impairment in cognition, mental health, and physical function after critical illness, which is associated with reduced quality of life and increased mortality. We recently have developed a clinically relevant animal model of PICS, which can mimic most features of human PICS. However, the underlying mechanism remains largely to be elucidated. Accumulating evidence has suggested that hippocampal GABAergic interneuron dysfunction is implicated in various mood disorders induced by stress.

Methods

We explored the role of hippocampal GABAergic interneurons and relevant neural activities in an animal model of PICS based on two-hit hypothesis. In addition, we tested whether fluoxetine treatment early following combined stress can prevent subsequent anatomical and behavioral pathologies.

Results

Here our study further supported our previous findings that this PICS model displayed reproducible anxiety- and depression like behavior and cognitive impairments, which resembles clinical features of human PICS. This behavioral state is accompanied by hippocampal neuroinflammation, reduced parvalbumin (PV) expression, and decreased theta and gamma power. Importantly, chronic fluoxetine treatment reversed most of these abnormalities.

Conclusions

Our study provides additional evidence that PV interneuron-mediated hippocampal network activity disruption might play a key role in the pathological of PICS, while fluoxetine offers protection via modulation of the hippocampal PV interneuron and relevant network activities.

Background

Medical advancements in the intensive care unit (ICU) have led to a substantial reduction in mortality rates in survivors of critical illness [1]. However, survivors frequently experience postintensive care syndrome (PICS), which is defined as a new or worsening impairment in cognition, mental health, and physical function that persist beyond their acute hospital admission [2]. It is estimated that more than 50% of these survivors of critical illness will experience at least one symptom of PICS, which not only
diminishes life quality of affected patients, but also poses a substantial issue in public health because of the increased prevalence in modern society [3, 4]. Therefore, more studies are needed to better understand the pathophysiology of PICS.

Chronic stress is one of the risk factors for the development of many neuropsychiatric diseases [5]. In patients admitted to ICU, they consistently face tremendous physical and psychological stressors, including social isolation, chemical and physical restraints, sleep disturbances due to exposure to noise and lights as well as other stressors [6, 7]. An earlier study reported that nearly 50% of patients experience symptoms of depression, anxiety, post-traumatic stress disorder, and cognitive impairment, which may persist for years [8]. Based on these findings, we recently have developed one clinically relevant animal model of PICS based on two-hit conception [9]. The “two-hit” hypothesis states that initial insult sensitizes the vulnerable brain to subsequent stress so that the two hits have synergistic toxic effects. Because bacterial infection remains the leading cause of ICU admission by epidemiological study [10], we thus subjected animals to lipopolysaccharide (LPS) injection as the first hit and subsequent chronic unpredictable stress as the second hit [9]. This model displayed reproducible anxiety- and depression like behavior and cognitive impairments, which mimics clinical features of human PICS [9]. However, the neural mechanism remains largely to be elucidated.

Accumulating evidence has documented that corticolimbic GABAergic dysfunction is implicated in the etiology of mood disorders, including schizophrenia, depression, and other related neuropsychiatric diseases [11–14]. Thus, the present study investigated whether GABAergic interneurons and its relevant neural activities are affected by our recently established animal model of PICS [9]. In addition, we examined whether pharmacological intervention with serotonergic system by fluoxetine, a selective serotonin reuptake inhibitor [15], could attenuate the neural and behavioral disturbances of PICS. In particular, we focused our interest on the hippocampus because this brain region plays a critical role in stress, emotion, and affective behaviors, and is susceptible to chronic stress exposure [5].

Materials And Methods

Animals
Seventy male C57BL/6 mice (3-4 months) were obtained and purchased from the animal center of Jinling Hospital, Nanjing University, Nanjing, China. Mice were housed under standard conditions in groups of three to four per cage in a temperature 24 ± 2 °C, humidity 55 ± 10% with access to water and food. Experimental protocols and monitoring for suffering were treated according to the National Institute of Health Guidelines on the use of laboratory animal and with approval of the Animal Care and Use Committee of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

**Combined stress protocol**

The combined stress protocol was selected as we described previously [9]. It is based on a two-hit conception, in which LPS injection as the first hit and subsequent modified chronic unpredictable stress as the second hit. Briefly, LPS (serotype 0111: B4, Sigma, Lot # 064M4125V, Shanghai, China) was diluted in 0.9% sterile saline and given intraperitoneally (i.p., 3 mg/kg) in a final injection volume of 0.2 ml. In the control group, mice received the same volume of 0.9% sterile saline to control for stress effect. For stress exposure, we selected certain relevant stressors that are frequently existed in critically ill patients living in the ICU. As our previous study described [9], animals were housed singly and exposed to four of the following stressors daily in a random order for 21 consecutive days (Table 1). The control, non-stressed mice groups were reared under similar conditions but received no stressors.

|       | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |
|-------|-------|-------|-------|-------|-------|-------|-------|
| Week 1 | C, D, G, H | A, C, F, G | B, D, F, H | A, B, C, G | B, D, E, F | A, D, F, H | B, C, F, G |
| Week 2 | A, B, E, H | A, C, E, G | B, C, D, G | A, B, D, H | C, E, F, G | A, E, G, H | A, E, F, G |
| Week 3 | B, C, F, G | B, E, G, H | A, D, F, G | A, C, G, H | A, B, D, E | B, C, D, H | C, D, F, H |

A, light on overnight (12 h); B, physical restraint for 6 h; C, cage tilt 45 °C for 12 h; D, lights-off for 3 h during the daylight phase; E, wet bedding overnight; F, odor overnight; G, noise in the room for 12 h; H, food and water deprivation overnight.

**Drug treatment**

To test the treatment effects of fluoxetine (Tocris Bioscience, Bristol, UK), it was dissolved in drinking water, which is the equivalent of 20 mg/kg/day 1 week after LPS injection until the end of the behavioral tests.

**Behavioral experiments**

Mice were transported and left for habituation to the testing room for 1 h prior to the behavioral tests.
as we previously described [9]. The order of the behavioral tests was open field, Y maze, novel object recognition, and sucrose preference tests. All behavioral tests were carried out between 9 and 12 AM on the designated day of experiment.

**Open field test**

The open field apparatus is made of a 50 × 50-cm rectangular arena and 40-cm-high walls. Each mouse was placed in the centre of the arena and was tested for general exploratory locomotion for 5 min. The total distance traveled in the arena and the time spent in central zones was scored using a computerized video-tracking system and software (XR-XZ301, Shanghai Softmaze Information Technology Co., Ltd., Shanghai, China). The apparatus was cleaned by using 70% ethanol after each mouse was tested.

**Y-maze**

The Y-maze was used to evaluate spatial working memory [16], which was performed in a black Plexiglas Y-Maze with three arms (30 cm long × 14 cm wide ×15 cm high) at 120° angles, designated A, B, and C. Each mouse was placed in the center of Y-Maze facing arm A and allowed to explore all three arms of the maze freely for 8 min. The sequence and total number of arms entered were recorded. Alternations were calculated when a mouse consecutively traveled to the three arms without re-entering the previously visited arms. The alternation rate was calculated using the following formula: Alternation rate (%) = number of alternations/(total number of arms entries - 2) × 100%.

**Novel object recognition test**

The novel object recognition (NOR) task was performed in an open field (40 cm × 60 cm wide × 50 cm tall) with three objects, two of which were almost the same, the other was different. Mice were habituated in NOR arena for 10 min in absence of testing objects for two days. Twenty-four hours later, the animal was exposed to two familiar objects for 10 min. To avoid a preference for one side of the open field, two familiar objects were counterbalanced between each mouse. In the testing trial, one of the objects was changed into a novel object with different color and shape. The exploration of the new object and familiar object was recorded by a video-tracking system for 10 min. The
discrimination score for novel object exploration ratio was calculated with the following formula: time exploring novel object/(time exploring novel object + time exploring familiar object)×100%.

Equipment and apparatus were cleaned using 70% ethanol between trials.

**Sucrose preference test**

Sucrose preference test is a well-accepted behavioral test measuring an anhedonia-like state. Anhedonia was measured by preference for a sucrose solution over water, using a two-bottle free choice method. Briefly, each mouse was presented simultaneously with two bottles, one with 1% sucrose solution and the other containing tap water. Mice were then given a free choice between either tap water or 1% sucrose in tap water solution for 24 h. After 12 h, the position of the two bottles was switched to control for a side preference in drinking behavior. Twenty-four hours later, the bottles were then weighed to measure how much liquid was consumed. The sum of water and sucrose intake was defined as the total intake, and sucrose preference was expressed as the percentage of sucrose intake from total intake. Sucrose preference was calculated as sucrose consumption / (sucrose consumption + water consumption) × 100%.

**Immunofluorescence**

Mice were deeply anesthetized with 2% sodium pentobarbital in saline (60 mg/kg, i.p.) and transcardically perfused with phosphate-buffered saline (PBS, pH 7.4), followed by 4% iced phosphate-buffered paraformaldehyde (PFA). Brains were removed and postfixed in the 4% PFA for 12 h and dehydrated in 30% sucrose at 4 °C overnight. Then brains were embedded in O.C.T. compound, and 30-μm-thick coronal sections were obtained using a Leica cryostat (CM 3050S) and restored in -70 °C for further use. Slices were initially blocked with 1-2% bovine serum albumin and 0.03% Triton X-100 for 2 h at room temperature and then incubated with the primary antibodies: rabbit anti-ionized calcium binding adapter molecule 1 (IBA1, 1:1000; WAKO, 019-19741), rabbit anti-glia fibrillary acidic protein (GFAP, 1:200, proteintech, 16825-1-AP), rabbit anti-PV (1:500; Abcam, ab11427), or rat anti-SST (1:500; Abcam, ab30788) overnight at 4 °C. Following washing 3 × 5 min in 1 × PBS, sections were incubated with secondary antibodies for 2 h at room temperature. After washing out the
secondary antibodies (Cy3-conjugated donkey anti-rat IgG (1:300; Santa Cruz Biotechnology, Dallas, TX) in 1 × PBS, sections were mounted on slides with 4′, 6-diamidino-2-pheny-lindole (DAPI) for 10 min. Detailed images were taken on an Olympus FV1000 confocal microscope. The intensities were calculated by Image J software (National Institutes of Health, Bethesda, MD, USA).

**Meso scale discovery (MSD)**

Inflammatory cytokines in the hippocampus were determined using multiplex biomarker assay platform from MSD, according to manufacturer’s instructions. Diluted protein extracts (50 ul) were loaded into a 96 well plates, along with standards. Plates were then sealed and incubated at room temperature for 2 h followed by three washes with phosphate buffered saline Tween. After adding the detection antibodies, plates were sealed and incubated for a further 2 h. Then read solution was added following three washes with PBST, and plates were immediately read using an MSD plate reader. The concentrations of inflammatory cytokines were expressed by pg/ml.

**In vivo electrophysiology**

For local field potential (LFP) recording, mice underwent an implant surgery as we previously described [17]. Briefly, mice were anesthetized with phenobarbital sodium (i.p., 40 mg/kg) and placed in a stereotaxic frame with precision micromanipulators. After craniotomy and removal of dura, an 8-channel linear silicon probes were used to record right CA1 region of the hippocampus. The coordinates were determined according to the mouse brain atlas in stereotaxic coordinates (posterior, 2.1 mm; lateral, 1.5-1.7 mm; depth, 1.7-2.1 mm). LFPs were recorded while the mice underwent the novel object recognition test. The signals were filtered with a pass-band of 0.3–300 Hz and were further amplified and digitized at 2 kHz. The recorded LFPs were filtered by a 50 Hz notching filter to remove the powerline artifact. For LFP analysis, the wideband recordings were down-sampled at 1000 Hz. All data analyses were performed by Neuroexplorer (Plexon Inc., Dallas, TX) software.

**Statistical analysis**

Data were analyzed and plotted by GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA). Data are presented as mean ± standard error of the mean (S.E.M.). The data were screened for normality and homogeneity of variance. For comparison of two groups, unpaired t-tests were used if the data
were normally distributed or Mann-Whitney tests if it was not. Multiple comparisons were analyzed by one-way ANOVA followed by Tukey’s test. The survival rate was estimated by Kaplan-Meier method and compared by the log-rank test. Bivariate relationships were evaluated using Pearson correlation coefficients. A $P < 0.05$ was considered statistically significant.

Results

Survival rate

To observe the effects of combined stress on mortality rate, we recorded survival rate during the experimental period. As shown in Fig. 1, no animals died in the control group (100% for control group). Animal death was observed in the first 4 days following combined stress protocol, but there was no difference in survival rate among groups ($P = 0.089$). The survival rate was 79.167% in LPS + stress (LS) group and 75% in LS + fluoxetine group.

Hippocampal inflammatory response induced by combined stress was attenuated by fluoxetine treatment

To determine changes in immune response in the hippocampus after combined stress, we performed immunostaining by using antibodies of IBA1 or GFAP, as well as MSD for inflammatory mediator measurements. Relative to control group, the intensity of IBA1 cells in the hippocampus increased significantly in LS group. Similarly, the intensity of hippocampal GFAP cells was significantly increased in LS group compared with control group. For inflammatory mediator measurements, we observed there was a significantly increased IL-6 level in the hippocampus in LS group than that in control group. These results suggested that combined stress induced an enhanced inflammatory reaction.

However, chronic treatment with fluoxetine only reversed the intensity of IBA1 (CA1: $F_{(2, 9)} = 9.236, P = 0.0066$; CA3: $F_{(2, 9)} = 5.029, P = 0.0342$; DG: $F_{(2, 9)} = 11.56, P = 0.0033$, Fig. 2) and GFAP (CA1: $F_{(2, 9)} = 22.35, P = 0.0003$; CA3: $F_{(2, 9)} = 5.993, P = 0.0221$; DG: $F_{(2, 9)} = 0.6033, P = 0.5677$, Fig. 3) of the CA1 region. The increased hippocampal IL-6 level in the LS group was also prevented by fluoxetine treatment ($F_{(2, 15)} = 4.964, P = 0.0222$, Fig. 4G). There was no difference in TNF-α ($F_{(2, 15)} = 0.7828, P = 0.4749$, Fig. 4B), IL-1β ($F_{(2, 15)} = 0.04009, P = 0.9608$, Fig. 4C), IL-2 ($F_{(2, 15)} = 0.1656, P = 0.8489$, Fig. 4D).
Fig. 4D), IL-4 ($F_{(2, 15)} = 1.738, P = 0.2094$, Fig. 4E), IL-5 ($F_{(2, 15)} = 0.3083, P = 0.7393$, Fig. 4F), IL-10 ($F_{(2, 15)} = 0.341, P = 0.7164$, Fig. 4H), IL-12p70 ($F_{(2, 15)} = 0.2097, P = 0.8132$, Fig. 4I), KC/GRO ($F_{(2, 15)} = 0.01621, P = 0.9839$, Fig. 4J), or INF-$\gamma$ ($F_{(2, 15)} = 0.1064, P = 0.8997$, Fig. 4K) in the hippocampus among groups.

PV interneuron deficit induced by combined stress was attenuated by fluoxetine treatment

To evaluate GABAergic interneuron changes in the hippocampus after combined stress, we performed immunostaining by antibodies raised against PV or SST, two major subgroups of GABAergic interneurons. As shown in Fig. 5, the intensity of PV was significantly decreased in the CA1 and CA3 regions of the hippocampus in LS group compared with control group, which were reversed by fluoxetine treatment (CA1: $F_{(2, 9)} = 7.65, P = 0.0115$; CA3: $F_{(2, 9)} = 7.252, P = 0.0133$). There was no difference in PV intensity of DG among groups ($F_{(2, 9)} = 0.271, P = 0.7686$). Surprisingly, we found combined stress did not affect SST (CA1: $t = 0.1253, P = 0.9044$; CA3: $t = 0.3095, P = 0.7674$; DG: $t = 0.1282, P = 0.9022$, Fig. 6) expression in all regions of the hippocampus. These results suggested this combined stress protocol selectively impaired hippocampal PV interneurons.

Altered hippocampal neural oscillations induced by combined stress were reversed by fluoxetine treatment

To further evaluate the causal role of altered oscillatory activities in the symptoms of PICS, we recorded LFP during novel object exploration test. Power spectral analysis showed that combined stress induced significantly decreased theta and gamma power when compared with control group. However, fluoxetine treatment reversed these deficits (theta: $F_{(2,15)} = 9.693, P = 0.002$; alpha: $F_{(2,15)} = 1.415, P = 0.2735$; beta: $F_{(2,15)} = 1.45, P = 0.2656$; gamma power: $F_{(2,15)} = 6.607, P = 0.0088$, Fig. 7D). In addition, linear regression analysis showed that theta or gamma oscillation was positively correlated with time spent with novel object (theta: $r = 0.6921, P = 0.0015$; gamma: $r = 0.7242, P = 0.001$, Fig. 7E-F). These data suggested that deficits in theta and gamma play an important role in cognition impairment.

Abnormal behavioral outcomes induced by combined stress were reversed by fluoxetine treatment
The open field test was performed to investigate locomotor activity and anxiety-like behavior. Although combined stress did not affect time spent in the center of the open arena ($F_{(2,33)} = 1.988$, $P = 0.1531$, Fig. 8B), it significantly increased the distance travelled as compared with the control group. This increase was prevented by fluoxetine treatment ($F_{(2,33)} = 17.32$, $P < 0.0001$, Fig. 8C).

Next, mice were tested in the spontaneous alternation Y-maze paradigm that assesses spatial working memory. The mice in LS group displayed significantly decreased spontaneous alteration than that in control group, which was reversed by fluoxetine treatment ($F_{(2,33)} = 8.044$, $P = 0.0014$, Fig. 8D). In the novel object recognition test, combined stress significantly decreased their exploration time with novel object ($F_{(2,33)} = 10.35$, $P = 0.0003$, Fig. 8E) and novel object recognition ratio ($F_{(2,33)} = 5.674$, $P = 0.0076$, Fig. 8F) compared with control group, while the decreased exploration time with novel object in LS group was prevented by fluoxetine treatment. In the sucrose preference test, mice showed significantly decreased preference for sucrose than controls, which was prevented by fluoxetine treatment ($F_{(2,33)} = 5.94$, $P = 0.0063$, Fig. 8G).

Discussion

By using this clinically relevant animal model of PICS, our study confirmed our previous finding that this PICS model displayed reproducible anxiety- and depression like behavior and cognitive impairments. More importantly, we found disturbed hippocampal PV interneuron and neural network in PICS, which can be precluded by fluoxetine treatment. Thus, our study reveals a mechanism of disturbed inhibitory neural network that may contribute to abnormal behavioral responses of PICS and also the efficacy of fluoxetine treatment.

Although the mortality of ICU patients has declined significantly in recent decades, morbidity after ICU discharge remains a significant concern [18]. It is important to point out that PICS is being increasingly recognized as a complication that affects more than 50% of critically ill patients, which has a profound impact on patients’ lives, including reduced quality of life and increased mortality [1–3]. With improvements in healthcare and increased numbers of ICU survivors, PICS is likely to become more prevalent and will continue to be a public health issue [6]. Although PICS is a multidimensional concept, each component has been studied separately. It is estimated
that more than 50% of all ICU survivors suffer from at least one or more PICS-related impairment [2]. Among them, depression, anxiety, cognitive impairment, and posttraumatic stress disorder related symptoms are the main components of psychological PICS [2, 3, 8, 19, 20]. Using a translational mouse model of PICS, we have recently shown that combined immune challenge with LPS and subsequent chronic stress induces synergistic pathological effects on behavioral outcomes [9], which were consistent with one recent study in which they showed depressive-like behavior in a two-hit model of depression by using LPS injection and subsequent chronic unpredictable mild stress protocol [21]. In the present study, we confirmed our previous finding that this two-hit hypothesis model of PICS displayed reproducible anxiety- and depression like behavior and cognitive impairments, suggesting this model is reliable. However, the underlying neural mechanism remains fully to be elucidated.

Environmental factors, such as trauma and stressful life events, profoundly alter neural structure and functional plasticity of the brain, drives changes in physiology and behavior, and contributes to a variety of mental disorders [5]. Although the mechanism underlying PICS remains largely unexplored, the pathobiology of psychiatric conditions is closely linked to inflammatory processes [22–24]. Similarly, we showed signs of hippocampal inflammation in the form of glia overactivation and hypersecretion of inflammatory cytokines. Thus, our study provides additional evidence that neuroinflammation may be a common mechanism contributing to stress-induced mental disorders. Of note, fluoxetine treatment down-regulated neuroinflammation and reversed some of the neurobehavioral abnormalities, suggesting neuroinflammation might play an initial and decisive role in PICS. Indeed, earlier studies have shown that chronic stress is associated with a chronic, low-grade inflammation in other models of neurodegenerative diseases [22–25]. Since we used a combined stress protocol, LPS challenge may act as an early toxic event and render the brain susceptible to subsequent chronic stress. Indeed, the synergistic relationship between inflammation and stress has been well described, in which stress can prime the immune system and thereby elicit an exaggerated response to a subsequent inflammatory stimulus and vice versa [25]. One question that remains unanswered is the underlying mechanism by which neuroinflammation induced symptoms of PICS.

Increasing evidence has suggested that cortical GABAergic interneurons play crucial roles in diverse brain functions [26]. The most extensively studied inhibitory interneurons are those that express PV or SST, which
comprise the majority of GABAergic system and exhibit distinct molecular and physiological properties [27]. There is extensive evidence that stress disrupts the structural integrity of specific GABAergic interneurons and this also affects the functioning of hippocampal GABAergic networks [28-31]. Preclinical data has shown that hippocampal PV or SST interneurons are vulnerable to psychosocial stressors, thus PV and SST deficits are frequently observed pathological features in depression and other neurological disorders with mood disturbances [32-34]. In our study, we evaluated these two subpopulations of GABAergic interneurons. Surprisingly, we found a reduction in the hippocampal PV but not SST interneurons in our model. Our data was in disagreement with previous findings, in which they showed that dysfunction of SST interneurons is likely associated with the pathophysiology of many mental disorders [35-37]. This discrepancy is likely to be due to differences in the two stress paradigms used, i.e. our study protocol includes initial immune challenge and is different from those induced by chronic stress. Overall, we provide further evidence supporting the role of GABAergic interneurons, especially hippocampal PV interneurons in the pathophysiology of PICS.

More importantly, these diverse subtypes of GABAergic interneurons play a key role in cognitive process as they provide networks of inhibition and orchestrate network oscillations [26, 38]. In particular, PV interneurons are implicated in mediating synchronization of oscillatory activities [26, 39]. By contrast, abnormal brain rhythms are considered to be as potential pathophysiological mechanisms causing mental diseases [40]. In further support of a link between PV interneurons and symptoms of PICS, we found that theta or gamma oscillation, a neurophysiological phenomenon that is supported by PV interneuron function, correlates positively with time with novel object. In one recent study, it is reported that PV and SST interneurons play a key role in hippocampal theta-nested gamma oscillations and long-term potentiation [41]. This is further supported by findings that changes in cortical gamma oscillation power and/or frequency can lead to various behavioral and cognitive effects [26, 39]. However, our study did not find a relation between these oscillations and anxiety or depression-like behavior. One explanation is likely to be that neuronal oscillation in the theta or gamma frequency range in the dorsal hippocampus is important for cognition performance but not for anxiety or depression-like behavior. Thus, our study provides a correlative link between behavioral alterations in PICS mice and the possible underlying cellular and network mechanisms.

Since GABAergic system has been proposed as a potential therapeutic target of antidepressant, we examined
whether treatment with the antidepressant fluoxetine offered protection by attenuating the neural and behavioral disturbances. Several studies have demonstrated that treatment with fluoxetine reverse the functional and structural impairments of the hippocampal formation induced by stress [9, 15, 42]. Although fluoxetine is designed to normalize monoaminergic transmission, it is now become widely accepted that its antidepressant mechanisms do not simply by increasing monoamine transmitter function and that alterations in these transmitter systems are not sufficient to explain the complex nature of affective disorders. There is accumulating evidence suggesting chronic fluoxetine treatment can increase GABAergic tone in the brain [43–45]. This is further confirmed by one recent study demonstrating that 5-HT5A signaling in PV interneurons mediates delayed antidepressant action of fluoxetine [46]. In addition, it has been demonstrated that antidepressant like fluoxetine mediated alteration of oscillations in the CA1 area and resulted in consequent cognitive effects [47]. In the current study, we showed that chronic fluoxetine treatment restored hippocampal PV interneuron deficit and alteration of oscillations, contributing to improved neurobehavioral outcomes. Our data together with previous findings suggested that chronic fluoxetine treatment offer protection via modulation of hippocampal PV interneurons and relevant network activities.

Conclusions
In summary, our study suggested that PV interneuron-mediated hippocampal network activity disruption might play a key role in the symptoms of PICS, while fluoxetine offers neuroprotection by reversing these abnormities. Thus, our data provide a possible mechanistic link between combined stress, hippocampal neuroinflammation, PV interneuron deficit, neural network disturbance, and symptoms of PICS. However, more specific studies are needed to confirm our results.

Abbreviations
GFAP, glial fibrillary acidic protein; LFP, For local field potential; LPS, lipopolysaccharide; MSD, meso scale discovery; IBA1, ionized calcium binding adapter molecule 1; ICU, intensive care unit; NOR, novel object recognition; PV, parvalbumin; PFA, paraformaldehyde; PBS, phosphate-buffered saline; PICS, Postintensive care syndrome; S.E.M. standard error of the mean.

Declarations

Acknowledgments
The authors thank Dr. Xia Zhu for her assistance on the use of the confocal microscope; Dr. Qinzhen Liu for
Production and Experimentation with Laboratory Animals; Dr. Bin Li for proofread the final draft of the manuscript.

Authors’ contributions
MH Ji and JH Tong performed most of the experiments, analyzed data, contributed to discussion, and wrote the first manuscript draft. ZQ Zhou and JJ Yang designed the main experiments, contributed to data analysis and discussion, and were responsible of the grant that financed the study. All the authors read and approved the final manuscript.

Funding
This study was supported by the grants from the National Natural Science Foundation of China (Nos., 81771156, 81772126), Jiangsu Province’s Key Provincial Talents Program (QNRC2016822), and Six Talent Peaks Project of Jiangsu Province (WSW-002).

Availability of data and materials
All datasets generated and/or analyzed in this study are available from the corresponding author on reasonable request.

Consent for publication
Yes.

Competing interests
The authors declare that they have no competing interests.

Ethics approval and consent to participate
Experimental protocols and monitoring for suffering were treated according to the National Institute of Health Guidelines on the use of laboratory animal and with approval of the Animal Care and Use Committee of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

References
1. Kondo Y, Fuke R, Hifumi T, Hatakeyama J, Takei T, Yamakawa K, et al. Early rehabilitation for the prevention of postintensive care syndrome in critically ill patients: a study protocol for a systematic review and meta-analysis. BMJ Open. 2017;7:e013828.
2. Marra A, Pandharipande PP, Girard TD, Patel MB, Hughes CG, Jackson JC, et al. Co-Occurrence of
3. Jackson JC, Pandharipande PP, Girard TD, Brummel NE, Thompson JL, Hughes CG, et al. Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study. Lancet Respir Med. 2014;2:369–79.

4. Davidson JE, Harvey MA, Bemis-Dougherty A, Smith JM, Hopkins RO. Implementation of the Pain, Agitation, and Delirium Clinical Practice Guidelines and promoting patient mobility to prevent post-intensive care syndrome. Crit Care Med United States. 2013;41:136-45.

5. Notaras M, van den Buuse M. Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Mol Psychiatry. England; 2020.

6. Luetz A, Grunow JJ, Mörgeli R, Rosenthal M, Weber-Carstens S, Weiss B, et al. Innovative ICU Solutions to Prevent and Reduce Delirium and Post-Intensive Care Unit Syndrome. Semin Respir Crit Care Med United States. 2019;40:673–86.

7. Lee M, Kang J, Jeong YJ. Risk factors for post-intensive care syndrome: A systematic review and meta-analysis. Aust Crit care Off J Confed Aust Crit Care Nurses. Australia; 2019.

8. Harvey MA. The truth about consequences-post-intensive care syndrome in intensive care unit survivors and their families. Crit. Care Med. United States; 2012. p. 2506-7.

9. Mao M, Li S, Zong M, Qiu L, Yang J, Xia J, et al. Two-hit model of postintensive care syndrome induced by lipopolysaccharide challenge and subsequent chronic unpredictable stress in mice. Int Immunopharmacol Netherlands. 2019;70:446–58.

10. Kahn JM, Davis BS, Yabes JG, Chang C-CH, Chong DH, Hershey TB, et al. Association Between State-Mandated Protocolized Sepsis Care and In-hospital Mortality Among Adults With Sepsis. JAMA. 2019;322:240–50.

11. Perez SM, Boley A, Lodge DJ. Region specific knockdown of Parvalbumin or Somatostatin produces neuronal and behavioral deficits consistent with those observed in schizophrenia.
2. Ren Z, Pribiag H, Jefferson SJ, Shorey M, Fuchs T, Stellwagen D, et al. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment. Biol Psychiatry. 2016;80:457–68.

3. Bast T, Pezze M, McGarrity S. Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition. Br J Pharmacol. 2017;174:3211–25.

4. Han K, Min J, Lee M, Kang B-M, Park T, Hahn J, et al. Neurovascular Coupling under Chronic Stress Is Modified by Altered GABAergic Interneuron Activity. J Neurosci. 2019;39:10081–95.

5. Du R-H, Tan J, Sun X-Y, Lu M, Ding J-H, Hu G. Fluoxetine Inhibits NLRP3 Inflammasome Activation: Implication in Depression. Int J Neuropsychopharmacol. 2016;19.

6. Qiu L-L, Pan W, Luo D, Zhang G-F, Zhou Z-Q, Sun X-Y, et al. Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca(2+)/calpain might contribute to postoperative cognitive dysfunction in aging mice. J Neuroinflammation. 2020;17:23.

7. Ji M, Li S, Zhang L, Gao Y, Zeng Q, Mao M, et al. Sepsis induced cognitive impairments by disrupting hippocampal parvalbumin interneuron-mediated inhibitory network via a D4-receptor mechanism. Aging. 2020;12:2471–84.

8. Hatch R, Young D, Barber V, Griffiths J, Harrison DA, Watkinson P. Anxiety, Depression and Post Traumatic Stress Disorder after critical illness: a UK-wide prospective cohort study. Crit Care. 2018;22:310.

9. Nikayin S, Rabiee A, Hashem MD, Huang M, Bienvenu OJ, Turnbull AE, et al. Anxiety symptoms in survivors of critical illness: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2016;43:23–9.

10. Rabiee A, Nikayin S, Hashem MD, Huang M, Dinglas VD, Bienvenu OJ, et al. Depressive Symptoms After Critical Illness: A Systematic Review and Meta-Analysis. Crit Care Med United States. 2016;44:1744–53.
1. Géa LP, Colombo R, Rosa ED da, Antqueviezc B, Aguiar ÉZ de, Hizo GH, et al. Anhedonic-like behavior correlates with IFNγ serum levels in a two-hit model of depression. Behav Brain Res Netherlands. 2019;373:112076.

2. Di Benedetto G, Burgaletto C, Carta AR, Saccone S, Lempereur L, Mulas G, et al. Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model. J Neuroinflammation. 2019;16:166.

3. Flores J, Noël A, Foveau B, Lynham J, Lecrux C, LeBlanc AC. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. Nat Commun. 2018;9:3916.

4. Rangasamy SB, Jana M, Roy A, Corbett GT, Kundu M, Chandra S, et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer’s pathology. J Clin Invest. 2018;128:4297–312.

5. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci. 2009;34:4–20.

6. Lim L, Mi D, Llorca A, Marín O. Development and Functional Diversification of Cortical Interneurons. Neuron. 2018;100:294–313.

7. DeFelipe J, López-Cruz PL, Benavides-Piccione R, Bielza C, Larrañaga P, Anderson S, et al. New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat. Rev. Neurosci. 2013. p. 202-16.

8. Mukherjee A, Carvalho F, Eliez S, Caroni P. Long-Lasting Rescue of Network and Cognitive Dysfunction in a Genetic Schizophrenia Model. Cell United States. 2019;178:1387-402.e14.

9. Gerhard DM, Pothula S, Liu R-J, Wu M, Li X-Y, Girgenti MJ, et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest United States. 2020;130:1336-49.

10. Xu H, Liu L, Tian Y, Wang J, Li J, Zheng J, et al. A Disinhibitory Microcircuit Mediates Conditioned
1. Murthy S, Kane GA, Katchur NJ, Lara Mejia PS, Obiofuma G, Buschman TJ, et al. Perineuronal Nets, Inhibitory Interneurons, and Anxiety-Related Ventral Hippocampal Neuronal Oscillations Are Altered by Early Life Adversity. Biol Psychiatry. 2019;85:1011–20.

2. Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M, et al. GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest. 2016;126:2482–94.

3. Kolata SM, Nakao K, Jeevakumar V, Farmer-Alroth EL, Fujita Y, Bartley AF, et al. Neuropsychiatric Phenotypes Produced by GABA Reduction in Mouse Cortex and Hippocampus. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2018;43:1445–56.

4. Czéh B, Varga ZKK, Henningsen K, Kovács GL, Miseta A, Wiborg O. Chronic stress reduces the number of GABAergic interneurons in the adult rat hippocampus, dorsal-ventral and region-specific differences. Hippocampus United States. 2015;25:393–405.

5. Fuchs T, Jefferson SJ, Hooper A, Yee P-H, Maguire J, Luscher B. Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state. Mol Psychiatry. 2017;22:920–30.

6. Miyata S, Kumagaya R, Kakizaki T, Fujihara K, Wakamatsu K, Yanagawa Y. Loss of Glutamate Decarboxylase 67 in Somatostatin-Expressing Neurons Leads to Anxiety-Like Behavior and Alteration in the Akt/GSK3β Signaling Pathway. Front Behav Neurosci. 2019;13:131.

7. Fee C, Banasr M, Sibille E. Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives. Biol Psychiatry. 2017;82:549–59.

8. Ognjanovski N, Schaeffer S, Wu J, Mofakham S, Maruyama D, Zochowski M, et al. Parvalbumin-expressing interneurons coordinate hippocampal network dynamics required for memory consolidation. Nat Commun. 2017;8:15039.

9. Hammer M, Krueger-Burg D, Tuffy LP, Cooper BH, Taschenberger H, Goswami SP, et al.
19

Perturbed Hippocampal Synaptic Inhibition and γ-Oscillations in a Neuroligin-4 Knockout Mouse Model of Autism. Cell Rep. 2015;13:516–23.

0. Sauer J-F, Strüber M, Bartos M. Impaired fast-spiking interneuron function in a genetic mouse model of depression. Elife. 2015;4.

1. Park K, Lee J, Jang HJ, Richards BA, Kohl MM, Kwag J. Optogenetic activation of parvalbumin and somatostatin interneurons selectively restores theta-nested gamma oscillations and oscillation-induced spike timing-dependent long-term potentiation impaired by amyloid β oligomers. BMC Biol. 2020;18:7.

2. Anderson ST, Commins S, Moynagh P, Coogan AN. Chronic fluoxetine treatment attenuates post-septic affective changes in the mouse. Behav Brain Res Netherlands. 2016;297:112–5.

3. Godavarthi SK, Sharma A, Jana NR. Reversal of reduced parvalbumin neurons in hippocampus and amygdala of Angelman syndrome model mice by chronic treatment of fluoxetine. J Neurochem England. 2014;130:444–54.

4. Filipović D, Stanisavljević A, Jasnić N, Bernardi RE, Inta D, Perić I, et al. Chronic Treatment with Fluoxetine or Clozapine of Socially Isolated Rats Prevents Subsector-Specific Reduction of Parvalbumin Immunoreactive Cells in the Hippocampus. Neuroscience United States. 2018;371:384–94.

5. Zhang W, Rosenkranz JA. Effects of Repeated Stress on Age-Dependent GABAergic Regulation of the Lateral Nucleus of the Amygdala. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2016;41:2309–23.

6. Sagi Y, Medrihan L, George K, Barney M, McCabe KA, Greengard P. Emergence of 5-HT5A signaling in parvalbumin neurons mediates delayed antidepressant action. Mol Psychiatry. England; 2019.

7. Méndez P, Pazienti A, Szabó G, Bacci A. Direct alteration of a specific inhibitory circuit of the hippocampus by antidepressants. J Neurosci. 2012;32:16616–28.
Survival rate. No animals died in the control group, the survival rate was 79.167% in LS group and 75% in LS + fluoxetine group (n = 18-24). Con, control; lipopolysaccharide; LPS, Flu, fluoxetine; LS, LPS + stress.
Fluoxetine treatment attenuated activation of microglia after combined stress. (A) Schematic timeline of the experimental procedure. (B-D) Representative images of IBA-1-positive cells in all subregions of the hippocampus. (E) Quantification of mean IBA-1 immufluorescence in the hippocampus. Data are shown as mean ± SEM (n = 4), *P < 0.05 vs control group, #P < 0.05 vs LS group, scale bar = 100 μm. Con, control; LPS, lipopolysaccharide; Flu, fluoxetine; IF, immufluorescence; LS, LPS + stress.
Fluoxetine treatment attenuated activation of astrocytes after combined stress. (A) Schematic timeline of the experimental procedure. (B-D) Representative images of GFAP-positive cells in all subregions of the hippocampus. (E) Quantification of mean GFAP immufluorescence in the hippocampus. Data are
Fluoxetine treatment attenuated IL-6 level after combined stress. (A) Schematic timeline of the experimental procedure. (B-K) Quantification of inflammatory mediators in the hippocampus. Data are shown as mean ± SEM (n = 6), *P < 0.05 vs control group, #P < 0.05 vs LS group. Con, control; LPS, lipopolysaccharide; Flu, fluoxetine; IF, immufluorescence; LS, LPS + stress.
Fluoxetine treatment attenuated PV deficit after combined stress. (A) Schematic timeline of the experimental procedure. (B-D) Representative images of PV interneurons in all subregions of the hippocampus. (E) Quantification of mean PV immunofluorescence in the hippocampus. Data are shown as mean ± SEM (n = 4), *P < 0.05 vs control group, #P < 0.05 vs LS group, scale bar = 100 μm. Con, control; LPS, lipopolysaccharide; Flu, fluoxetine; IF, immunofluorescence; LS, LPS + stress.
Combined stress did not affect SST level. (A) Schematic timeline of the experimental procedure. (B-D) Representative images of SST interneurons in all subregions of the hippocampus. (E) Quantification of mean SST immufluorescence in the hippocampus. Data are shown as mean ± SEM (n = 4), scale bar = 100 μm. Con, control; LPS, lipopolysaccharide; Flu, fluoxetine; IF, immufluorescence; LS, LPS + stress.
Altered hippocampal neural oscillations induced by combined stress were reversed by fluoxetine treatment. (A) Schematic timeline of the experimental procedure. (B) Representative images of local field potential in the CA1 of the hippocampus. (C) Quantification of local field potential in the CA1 of the
Abnormal behavioral outcomes induced by combined stress were reversed by fluoxetine treatment. (A) Schematic timeline of the experimental procedure. (B) There was no difference in time spent in the
center in the open arena among groups. (C) Combined stress significantly increased distance travelled compared with control group, which was prevented by fluoxetine treatment. (D) Mice in LS group displayed significantly decreased spontaneous alteration than that in control group, which was reversed by fluoxetine treatment. (E) Combined stress induced significantly decreased time with the novel object, which was prevented by fluoxetine treatment. (F) Combined stress induced significantly decreased recognition ratio was not prevented by fluoxetine treatment. (G) Combined stress induced significantly decreased preference for sucrose was prevented by fluoxetine treatment. Data are shown as mean ± SEM (n = 12), *P < 0.05 vs control group, #P < 0.05 vs LS group. Con, control; LPS, lipopolysaccharide; Flu, fluoxetine; LS, LPS + stress.